No products in the cart.
Mouse Monoclonal Anti-MLH1 antibody (STJ99207)
Supplier: St John’s Laboratory Ltd.
Recommended applications: WB, ELISA
Recommended dilution: WB 1:500-2000; ELISA 1:10000-20000
Recommended protocols: check protocols
Click or hover above images to see image description for Anti-MLH1 antibody.
Check alternative names for the antibodyExpand
|COCA 2 antibody|COCA2 antibody|DNA mismatch repair protein Mlh1 antibody|FCC 2 antibody|FCC2 antibody|hMLH 1 antibody|hMLH1 antibody|HNPCC 2 antibody|HNPCC antibody|HNPCC2 antibody|MGC5172 antibody|MLH 1 antibody|MLH1 antibody|MLH1_HUMAN antibody|MutL homolog 1 (E. coli) antibody|MutL homolog 1 antibody|MutL homolog 1 colon cancer nonpolyposis type 2 antibody|MutL homolog 1, colon cancer, nonpolyposis type 2 (E. coli) antibody|MutL protein homolog 1 antibody|MutL, E. coli, homolog of, 1 antibody|Anti-MLH1 antibody [EPR3894] (ab92312)
SCBT cat No: sc-133228|sc-271978|sc-582|sc-56160|sc-166625|sc-56161|sc-11442|sc-581|
|Catalogue No.|| |
Anti-MLH1 antibody detects endogenous levels of MLH1 and does not cross-react with related proteins.
Purified recombinant human MLH1 protein fragments expressed in E.coli.
|Recommended dilution|| |
WB 1:500-2000; ELISA 1:10000-20000
|Molecular weight|| |
Anti-MLH1 antibody was tube-contained in liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Anti-MLH1 antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
-20 Celsius degree. Avoid repeated freeze/thaw cycles.
|Alternative antibody names|| |
COCA 2 antibody, COCA2 antibody, DNA mismatch repair protein Mlh1 antibody, FCC 2 antibody, FCC2 antibody, hMLH 1 antibody, hMLH1 antibody, HNPCC 2 antibody, HNPCC antibody, HNPCC2 antibody, MGC5172 antibody, MLH 1 antibody, MLH1 antibody, MLH1_HUMAN antibody, MutL homolog 1 (E. coli) antibody, MutL homolog 1 antibody, MutL homolog 1 colon cancer nonpolyposis type 2 antibody, MutL homolog 1, colon cancer, nonpolyposis type 2 (E. coli) antibody, MutL protein homolog 1 antibody, MutL, E. coli, homolog of, 1 antibody
|Database links|| |
|Protein function|| |
Heterodimerizes with PMS2 to form MutL alpha, a component of the post-replicative DNA mismatch repair system (MMR). DNA repair is initiated by MutS alpha (MSH2-MSH6) or MutS beta (MSH2-MSH6) binding to a dsDNA mismatch, then MutL alpha is recruited to the heteroduplex. Assembly of the MutL-MutS-heteroduplex ternary complex in presence of RFC and PCNA is sufficient to activate endonuclease activity of PMS2. It introduces single-strand breaks near the mismatch and thus generates new entry points for the exonuclease EXO1 to degrade the strand containing the mismatch. DNA methylation would prevent cleavage and therefore assure that only the newly mutated DNA strand is going to be corrected. MutL alpha (MLH1-PMS2) interacts physically with the clamp loader subunits of DNA polymerase III, suggesting that it may play a role to recruit the DNA polymerase III to the site of the MMR. Also implicated in DNA damage signaling, a process which induces cell cycle arrest and can lead to apoptosis in case of major DNA damages. Heterodimerizes with MLH3 to form MutL gamma which plays a role in meiosis. .
|Protein tissue specificity|| |
Colon, lymphocytes, breast, lung, spleen, testis, prostate, thyroid, gall bladder and heart.
|Involvement in disease|| |
Hereditary non-polyposis colorectal cancer 2 (HNPCC2) [MIM:609310]: An autosomal dominant disease associated with marked increase in cancer susceptibility. It is characterized by a familial predisposition to early-onset colorectal carcinoma (CRC) and extra-colonic tumors of the gastrointestinal, urological and female reproductive tracts. HNPCC is reported to be the most common form of inherited colorectal cancer in the Western world. Clinically, HNPCC is often divided into two subgroups. Type I is characterized by hereditary predisposition to colorectal cancer, a young age of onset, and carcinoma observed in the proximal colon. Type II is characterized by increased risk for cancers in certain tissues such as the uterus, ovary, breast, stomach, small intestine, skin, and larynx in addition to the colon. Diagnosis of classical HNPCC is based on the Amsterdam criteria: 3 or more relatives affected by colorectal cancer, one a first degree relative of the other two; 2 or more generation affected; 1 or more colorectal cancers presenting before 50 years of age; exclusion of hereditary polyposis syndromes. The term ‘suspected HNPCC’ or ‘incomplete HNPCC’ can be used to describe families who do not or only partially fulfill the Amsterdam criteria, but in whom a genetic basis for colon cancer is strongly suspected. . Note=The disease is caused by mutations affecting the gene represented in this entry.; Mismatch repair cancer syndrome (MMRCS) [MIM:276300]: An autosomal recessive, rare, childhood cancer predisposition syndrome encompassing a broad tumor spectrum. This includes hematological malignancies, central nervous system tumors, Lynch syndrome-associated malignancies such as colorectal tumors as well as multiple intestinal polyps, embryonic tumors and rhabdomyosarcoma. Multiple cafe-au-lait macules, a feature reminiscent of neurofibromatosis type 1, are often found as first manifestation of the underlying cancer. Areas of skin hypopigmentation have also been reported in MMRCS patients. . Note=The disease is caused by mutations affecting the gene represented in this entry.; Muir-Torre syndrome (MRTES) [MIM:158320]: Rare autosomal dominant disorder characterized by sebaceous neoplasms and visceral malignancy. . Note=The disease is caused by mutations affecting the gene represented in this entry.; Note=Defects in MLH1 may contribute to lobular carcinoma in situ (LCIS), a non-invasive neoplastic disease of the breast.; Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; Note=Some epigenetic changes can be transmitted unchanged through the germline (termed ‘epigenetic inheritance’). Evidence that this mechanism occurs in humans is provided by the identification of individuals in whom 1 allele of the MLH1 gene is epigenetically silenced throughout the soma (implying a germline event). These individuals are affected by HNPCC but does not have identifiable mutations in MLH1, even though it is silenced, which demonstrates that an epimutation can phenocopy a genetic disease.; Colorectal cancer (CRC) [MIM:114500]: A complex disease characterized by malignant lesions arising from the inner wall of the large intestine (the colon) and the rectum. Genetic alterations are often associated with progression from premalignant lesion (adenoma) to invasive adenocarcinoma. Risk factors for cancer of the colon and rectum include colon polyps, long-standing ulcerative colitis, and genetic family history. . Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.
|Protein sequence and domain|| |
Belongs to the DNA mismatch repair MutL/HexB family.
|Protein cellular localization|| |
AntibodyPlus can customize Anti-MLH1 antibody according to your requirement, including bulk product size,etc. Please contact email@example.com. AntibodyPlus provide antibody trial sample for your own antibody validation and collects antibody reviews.
St John’s Laboratory Ltd.
|Product type|| |
There are no reviews for this product yet.
By submitting a review, get following benefits:
1. Receive $50 ABcoins as credit for each review.
2. First trial sample order will be fully refunded as credit.
3. Have a chance to win a $50 amazon gift card!
There is no extra validation for this product yet.
Check other extra validated antibodies below: